English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 18 June 2020, 11:00 HKT/SGT
Share:
    

Source: Novotech
Novotech Partners with South Korea's Pusan National University Hospital

BUSAN, SOUTH KOREA, June 18, 2020 - (ACN Newswire) - The leading Asia-Pacific biotech specialist CRO Novotech has partnered with South Korea's world-class Pusan National University Hospital (PNUH). The Partnership is designed to further support Novotech's biotech clients run their clinical trials in the region.




Dr. Jeong Zoo Lee, the President of PNUH, said: "The PNUH site team and Novotech have worked together on a number of studies already. We have progressed to a formal agreement to support Novotech's biotech clients across all clinical research and patient recruitment areas.

"We are pleased to partner with a regional CRO leader with such an outstanding reputation internationally," said Dr. Lee.

Dr. Yooni Kim, Executive Director, Asia Operations said: "Novotech was very pleased to establish a Partnership with PNUH, which has completed more than 340 clinical trials and is ranked 7th in terms of number of clinical trials in South Korea *GlobalData.

"The PNUH site offers biotechs quality infrastructure, world-class medical and hospital facilities, as well as South Korea's supportive rapid start-up environment. The main therapeutic areas at PNUH have been oncology, infectious disease, cardiovascular and gastrointestinal," said Dr. Kim.

Novotech now has over 20 significant Partnerships with some of the leading medical institutions in the region. The Partnership Program is strategically designed to deliver unparalleled access to quality investigators, KOLs, and up to 4 million patients for its international biotech clients.

About Novotech - https://novotech-cro.com

Novotech is internationally recognized as the leading regional full-service contract research organization (CRO) in Asia-Pacific. Novotech has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotechnology companies. Novotech was established in 1996, with offices in 11 locations across the region, and site partnerships with major health institutions.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech obtained the ISO 27001 certification which is the best-known standard in the ISO family providing requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies.

For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

Media contact:
David James
[email protected]
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427


Topic: Clinical Trial Results
Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Novotech Releated News
Sept 28, 2020 14:00 HKT/SGT
노보텍 (Novotech), 파마 인텔리전스 (Pharma Intelligence)의 사이트라인 어워드 2020 (Citeline Awards 2020) 최종후보로 선정
Sept 9, 2020 12:00 HKT/SGT
노보텍 (Novotech), 식품의약품안전처 (MFDS) 임상시험 승인 상위 임상시험수탁기관 (CRO) 진입
Sept 1, 2020 09:00 HKT/SGT
아시아 태평양 지역 임상시험수탁기관 (CRO) 리더 노보텍 (Novotech), ‘2020년 프로스트 & 설리번 올해의 아시아-태평양 지역 임상시험수탁기관’ 상 수상
Aug 27, 2020 14:00 HKT/SGT
Novotech 作为亚太地区 CRO 领军者–荣膺“Frost & Sullivan 亚太地区合同研究组织(CRO)2020 年度企业”称号
Aug 27, 2020 14:00 HKT/SGT
Novotech 作為亞太地區 CRO 領軍者–榮膺“Frost & Sullivan 亞太地區合同研究組織(CRO)2020 年度企業”稱號
More news >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575